Technical Analysis for RAIN - Rain Therapeutics Inc.

Grade Last Price % Change Price Change
D 14.08 1.88% 0.26
RAIN closed up 1.88 percent on Monday, October 25, 2021, on 79 percent of normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong N/A Down Up
Historical RAIN trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Doji - Bearish? Reversal 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.88%
Narrow Range Bar Range Contraction 1.88%
NR7 Range Contraction 1.88%
NR7-2 Range Contraction 1.88%
Up 3 Days in a Row Strength 1.88%
Older End-of-Day Signals for RAIN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
20 DMA Resistance about 17 hours ago
Rose Above 20 DMA about 19 hours ago
10 DMA Support about 19 hours ago
60 Minute Opening Range Breakout about 19 hours ago
Up 5% about 19 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is RAIN-32, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing RAIN-32 that has completed Phase II clinical trial in liposarcoma, Phase I clinical trial in solid tumors, and Phase II clinical trial in intimal sarcoma, as well as RAD52 for tumors, including breast, ovarian, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Solid Tumors Cancers Prostate Cancer Antineoplastic Drugs Tumors Targeted Therapy Tyrosine Kinase Receptors Bemcentinib

Is RAIN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 23.9
52 Week Low 11.57
Average Volume 59,307
200-Day Moving Average 0.00
50-Day Moving Average 15.62
20-Day Moving Average 14.22
10-Day Moving Average 13.98
Average True Range 0.99
ADX 26.77
+DI 17.56
-DI 26.24
Chandelier Exit (Long, 3 ATRs) 13.52
Chandelier Exit (Short, 3 ATRs) 14.55
Upper Bollinger Bands 15.87
Lower Bollinger Band 12.57
Percent B (%b) 0.46
BandWidth 23.20
MACD Line -0.50
MACD Signal Line -0.58
MACD Histogram 0.078
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 15.32
Resistance 3 (R3) 15.34 14.94 15.11
Resistance 2 (R2) 14.94 14.62 14.93 15.04
Resistance 1 (R1) 14.51 14.43 14.31 14.49 14.98
Pivot Point 14.11 14.11 14.01 14.10 14.11
Support 1 (S1) 13.68 13.80 13.48 13.67 13.18
Support 2 (S2) 13.28 13.60 13.28 13.12
Support 3 (S3) 12.86 13.28 13.05
Support 4 (S4) 12.84